The Role of Tumor-related LncRNA PART1 in Cancer
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: As it is known, long non-coding RNA (lncRNA) affects tumor progression, which has caused a great upsurge in recent years. It can also affect the growth, migration, and invasion of tumors. The abnormal expression of lncRNA is associated with malignant tumors. In addition, it has been proved that lncRNA is a key targeted gene for the treatment of some diseases. PART1, a member of lncRNA, has been reported as a regulator in the process of tumor occurrence and development. This study aims to reveal the biological functions, specific mechanisms, and clinical significance of PART1 in various tumor cells.
METHODS: Through the careful search of PUBMED, the mechanisms of the effect of PART1 on tumorigenesis and development are summarized.
RESULTS: On the one hand, the up-regulated expression of PART1 plays a tumor-promoting role in tumors, including lung cancer, prostate cancer, bladder cancer, and so on. On the other hand, PART1 is down-regulated in gastric cancer, glioma, and other tumors to play a tumor inhibitory role. In addition, PART1 regulates tumor growth mainly by targeting microRNA, such as miR-635, directly regulating the expression of proteins, such as FUS/EZH2, affecting signal pathways, such as Toll-like receptor pathway, or regulating immune cells.
CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumortargeted therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 27(2021), 40 vom: 04., Seite 4152-4159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jinlan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 28.03.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1381612827666210705161955 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327722118 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327722118 | ||
| 003 | DE-627 | ||
| 005 | 20231225201418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612827666210705161955 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327722118 | ||
| 035 | |a (NLM)34225608 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jinlan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of Tumor-related LncRNA PART1 in Cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: As it is known, long non-coding RNA (lncRNA) affects tumor progression, which has caused a great upsurge in recent years. It can also affect the growth, migration, and invasion of tumors. The abnormal expression of lncRNA is associated with malignant tumors. In addition, it has been proved that lncRNA is a key targeted gene for the treatment of some diseases. PART1, a member of lncRNA, has been reported as a regulator in the process of tumor occurrence and development. This study aims to reveal the biological functions, specific mechanisms, and clinical significance of PART1 in various tumor cells | ||
| 520 | |a METHODS: Through the careful search of PUBMED, the mechanisms of the effect of PART1 on tumorigenesis and development are summarized | ||
| 520 | |a RESULTS: On the one hand, the up-regulated expression of PART1 plays a tumor-promoting role in tumors, including lung cancer, prostate cancer, bladder cancer, and so on. On the other hand, PART1 is down-regulated in gastric cancer, glioma, and other tumors to play a tumor inhibitory role. In addition, PART1 regulates tumor growth mainly by targeting microRNA, such as miR-635, directly regulating the expression of proteins, such as FUS/EZH2, affecting signal pathways, such as Toll-like receptor pathway, or regulating immune cells | ||
| 520 | |a CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumortargeted therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a LncRNA | |
| 650 | 4 | |a PART1 | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a clinical prognosis | |
| 650 | 4 | |a treatment. | |
| 650 | 4 | |a tumor | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a PART-1 RNA, human |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a RNA, Untranslated |2 NLM | |
| 700 | 1 | |a Meng, Enqing |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yexiang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yujie |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Chengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Chengfu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 27(2021), 40 vom: 04., Seite 4152-4159 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:40 |g day:04 |g pages:4152-4159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1381612827666210705161955 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 40 |b 04 |h 4152-4159 | ||